Insider Buying: GSK (LON:GSK) Insider Purchases 1,650 Shares of Stock

GSK plc (LON:GSK) insider Jonathan Symonds bought 1,650 shares of the firm’s stock in a transaction dated Monday, December 22nd. The shares were acquired at an average price of GBX 1,810 per share, with a total value of £29,865.

GSK Trading Up 0.5%

Shares of LON GSK traded up GBX 9.75 during mid-day trading on Monday, reaching GBX 1,810. The company had a trading volume of 2,065,858,250 shares, compared to its average volume of 19,663,850. The stock has a market cap of £73.08 billion, a price-to-earnings ratio of 13.61, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK plc has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 1,853.50. The business’s 50-day moving average is GBX 1,758.28 and its 200-day moving average is GBX 1,565.36. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of recent research reports. Berenberg Bank increased their price target on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Shore Capital reiterated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a report on Monday, October 20th. JPMorgan Chase & Co. raised their target price on shares of GSK from GBX 1,400 to GBX 1,500 and gave the company an “underweight” rating in a research report on Friday, November 7th. Finally, Jefferies Financial Group upped their price target on shares of GSK from GBX 2,000 to GBX 2,100 and gave the stock a “buy” rating in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, GSK has an average rating of “Hold” and a consensus price target of GBX 1,762.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.